Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ADA | P00813 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260647 | 0.86 | GPR84 (0.37) | NR1I2LOXL2SLC2A1GPR84ADA | |
| SCHEMBL22299579 | 0.84 | LOXL2 (0.36) | NR1I2LOXL2SLC2A1GPR84ADA | |
| SCHEMBL174988 | 0.83 | NR1I2 (0.39) | NR1I2SLC2A1GPR84ADATBXAS1 | |
| SCHEMBL25150378 | 0.82 | UHRF1 (0.38) | NR1I2SLC2A1GPR84ADATBXAS1 | |
| SCHEMBL3443064 | 0.81 | NOS3 (0.43) | NR1I2SLC2A1GPR84ADAKDM4E | |
| SCHEMBL22458264 | 0.81 | NR1I2 (0.37) | NR1I2LOXL2SLC2A1GPR84ADA | |
| SCHEMBL3443825 | 0.81 | AR (0.38) | NR1I2SLC2A1GPR84ADATBXAS1 | |
| SCHEMBL19304419 | 0.80 | LOXL2 (0.41) | NR1I2LOXL2SLC2A1GPR84KDM4E | |
| SCHEMBL18948475 | 0.80 | LOXL2 (0.41) | NR1I2LOXL2SLC2A1GPR84KDM4E | |
| SCHEMBL20372917 | 0.80 | LOXL2 (0.38) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | PIK3C3, ERG28, DDT | NR1I2 3733/4885LOXL2 3378/4885SLC2A1 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.